Tmunity Therapeutics, a US-based immunotherapy spinout from University of Pennsylvania, completed a $100m series A round today featuring the institution and Parker Institute for Cancer Immunotherapy.
Biopharmaceutical firm Gilead Sciences, insurance provider Ping An, pharmaceutical firm Eli Lilly and cellular research provider Be The Match BioTherapies also took part. Ping An and Eli Lilly invested through their respective units Ping An Ventures and Lilly Asia Ventures.
Tmunity is developing T cell immunotherapy treatments for patients suffering from cancer, infectious diseases…